(NASDAQ: SLNO) Soleno Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 58.6%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.57%.
Soleno Therapeutics's revenue in 2025 is $0.On average, 5 Wall Street analysts forecast SLNO's revenue for 2025 to be $2,010,919,423, with the lowest SLNO revenue forecast at $1,189,800,711, and the highest SLNO revenue forecast at $2,549,932,909. On average, 5 Wall Street analysts forecast SLNO's revenue for 2026 to be $12,056,647,204, with the lowest SLNO revenue forecast at $11,613,785,338, and the highest SLNO revenue forecast at $12,744,625,150.
In 2027, SLNO is forecast to generate $30,485,808,558 in revenue, with the lowest revenue forecast at $25,091,138,245 and the highest revenue forecast at $40,194,199,366.